Wastewater treatment by local microalgae strains for CO2 sequestration and biofuel production

Currently, the scientific community is keenly working on environmental-friendly processes for the production of clean energy and sustainable development. The study was conducted to cultivate microalgae in raw institutional wastewater for water treatment, enriched production of biomass and CO2 sequestration. The strains which were used in this study are Scenedesmus sp. and Chlorella sp. which were isolated from Kallar Kahar Lake, Pakistan. Both strains were cultivated in synthetic growth medium (Bold's Basal Medium) to enhance biomass production. Afterward, microalgae cultures were inoculated in wastewater sample in mixotrophic mode under ambient conditions. The impurities in wastewater were successfully removed from the original sample by the 7th day of operation. COD 95%, nitrate 99.7% and phosphate 80.5% were removed by applying Scenedesmus sp. Meanwhile, Chlorella sp. reduced 84.86% COD, 98.2% nitrate and 70% phosphate, respectively. Interestingly, sulfates were removed from wastewater completely by both strains. Besides being useful in wastewater remediation, these microalgae strains were subsequently harvested for lipid extraction and potential biofuel production was determined. Therefore, the applied method is an environmentally safe, cost-effective and alternative technology for wastewater treatment. Furthermore, the achieved biomass through this process can be used for the production of biofuels

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Abstract: Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown